Trials / Completed
CompletedNCT00263549
Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis
Multicenter Study for Evaluation of Efficacy and Safety of Perennial Specific Immunotherapy With a Depot House Dust Mite Allergen Extract (D. Pteronyssinus 100%) in Patients With House Dust Mite Sensitivity
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Allergopharma GmbH & Co. KG · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | House dust mite Novo Helisen Depot |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2005-02-01
- Completion
- 2006-02-01
- First posted
- 2005-12-09
- Last updated
- 2013-02-11
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00263549. Inclusion in this directory is not an endorsement.